Hao Wu
Dr. Hao Wu is the Founder and CEO of Nanomics Biotech, a venture-backed company transforming precision medicine by democratizing large-scale proteomics and artificial intelligence-driven biomarker discovery. With a strong track record in AI-powered healthcare innovation, Dr. Wu leads the development of high-throughput proteomic platforms to advance biomarker research, early disease detection, and personalized medicine.
Dr. Wu began his career at ARCH Venture Partners, focusing on early-stage biotech investments. He then transitioned into product leadership roles at several digital biomarker and diagnostic startups.
Prior to his entrepreneurial journey, Dr. Wu conducted extensive research at Argonne National Laboratory, Oak Ridge National Laboratory, and the Stanford National Accelerator Laboratory, where he specialized in molecular simulation and ultrafast experimental characterization of polypeptide nanocarriers. His work integrated theory, simulation, and high-resolution structural biology to study nanoparticle dynamics with nanoscale precision.
Dr. Wu holds a Ph.D. in Molecular Engineering from the University of Chicago, with interdisciplinary expertise spanning nanomedicine and soft matter physics.
Abstracts this author is presenting: